REVBW REVELATION BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, REVELATION BIOSCIENCES INC reported revenue of n/a, net income of −$3.32M and diluted EPS of −$0.87; for the fiscal year ended December 2025 revenue was n/a.
REVBW annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$9.07M, net income −$8.91M (margin n/a), EPS −$23.95
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$7.98M, net income −$15.0M (margin n/a), EPS −$1052.16
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$8.66M, net income −$120K (margin n/a), EPS −$8.44
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$10.9M, net income −$10.8M (margin n/a), EPS −$149.20
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$12.0M, net income −$12.0M (margin n/a), EPS −$42.50
REVBW quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.32M, EPS −$0.87
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.01M, EPS −$2.71
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.51M, EPS $31.20
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.91M, EPS −$1.77
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.44M, EPS −$28.04
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.05M, EPS −$25.34
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.73M, EPS −$726.37
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.24M, EPS −$40.15
- Quarter ended Jun 30, 2024: revenue n/a, net income −$8.39M, EPS −$246.27
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.68M, EPS −$39.37
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$2.20M, EPS −$29.74
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.63M, EPS −$9.94
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.45M, EPS −$5.83
- Quarter ended Mar 31, 2023: revenue n/a, net income $6.16M, EPS $37.07
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$1.21M, EPS −$127.23
- Quarter ended Sep 30, 2022: revenue n/a, net income −$1.17M, EPS −$1.91
- Quarter ended Jun 30, 2022: revenue n/a, net income −$1.83M, EPS −$4.16
- Quarter ended Mar 31, 2022: revenue n/a, net income −$6.62M, EPS −$15.90
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.86M, EPS −$41.21
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.04M, EPS −$0.48
REVBW cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$8.27M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$18.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$7.29M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$11.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$11.1M, share buybacks $35.5M
REVBW balance sheet
- Jun 30, 2026: cash $11.5M, total assets $12.5M, total liabilities $2.43M, shareholders' equity $10.1M
- Mar 31, 2026: cash $14.1M, total assets $15.0M, total liabilities $2.06M, shareholders' equity $13.0M
- Dec 31, 2025: cash $10.7M, total assets $11.6M, total liabilities $2.72M, shareholders' equity $8.86M
- Sep 30, 2025: cash $12.7M, total assets $12.9M, total liabilities $1.85M, shareholders' equity $11.0M
- Jun 30, 2025: cash $5.17M, total assets $5.40M, total liabilities $1.57M, shareholders' equity $3.83M
- Mar 31, 2025: cash $3.70M, total assets $3.97M, total liabilities $1.09M, shareholders' equity $2.88M
- Dec 31, 2024: cash $6.50M, total assets $6.62M, total liabilities $1.91M, shareholders' equity $4.71M
- Sep 30, 2024: cash $6.54M, total assets $6.74M, total liabilities $4.07M, shareholders' equity $2.67M
Is REVBW profitable?
No. REVELATION BIOSCIENCES INC lost $10.8M over the last four quarters.
What is REVBW's EPS?
Diluted earnings per share over the last four quarters were $25.85; −$0.87 in the latest quarter.